Higher multimorbidity (CCI ≥4 vs 1) was independently associated with increased 30-day readmission risk after COPD hospitalization (aOR 2.00; 95% CI 1.33–2.99; P=0.003).
Observational (n=2,774)
No
Does risk adjustment for multimorbidity and frailty alter the interpretation of temporal trends in 30-day readmission risk after COPD hospitalisation?
Risk adjustment for multimorbidity and frailty is essential for valid interpretation of COPD 30-day readmission performance metrics.
Odds Ratio: 2 (95% CI 1.33–2.99)
p-value: p=0.003
Introduction: The 30-day readmission rate for chronic obstructive pulmonary disease (COPD) is a common performance metric but may be confounded by factors unrelated to quality of care. Our aim was to assess how sociodemographic factors, multimorbidity and frailty impact 30-day readmission risk after COPD hospitalisation, and whether risk adjustment alters interpretation of temporal trends. Method: This is a retrospective analysis of administrative data from October 2017 to June 2023 from Changi General Hospital, Singapore. Multivariable mixed-effects logistic regression models were used to estimate unadjusted and risk-adjusted 30-day readmission odds. Covariates included age, sex, race, Charlson Comorbidity Index (CCI), Hospital Frailty Risk Score (HFRS) and year. Temporal trends in readmission risk were compared across unadjusted and adjusted models. Results: Of the 2774 admissions, 749 (27%) resulted in 30-day readmissions. Higher CCI (CCI≥4 versus vs CCI=1: adjusted odds ratio aOR 2.00, 95% confidence interval CI 1.33–2.99, P=0.003; CCI 2–3 vs CCI=1: aOR 1.50, 95% CI 1.15–1.96, P=0.001) and higher HFRS (≥5 vs <5: aOR 1.29, 95% CI 1.01–1.65, P=0.04) were independently associated with increased readmission risk. While unadjusted analyses showed no significant temporal trends, the risk-adjusted model revealed a 32–35% reduction in readmission odds in 2021–2023 compared to baseline. Conclusion: Multimorbidity and frailty significantly impact COPD readmissions. Risk adjustment revealed improvements in readmission risk not evident in unadjusted analyses, emphasising the importance of applying risk adjustments to ensure valid performance metrics.
Yii et al. (Mon,) conducted a observational in Chronic obstructive pulmonary disease (COPD) (n=2,774). Higher multimorbidity (CCI ≥4) vs. CCI = 1 was evaluated on 30-day readmission (aOR 2.00, 95% CI 1.33-2.99, p=0.003). Higher multimorbidity (CCI ≥4 vs 1) was independently associated with increased 30-day readmission risk after COPD hospitalization (aOR 2.00; 95% CI 1.33–2.99; P=0.003).